Hepatology· 2018Q1
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- 4,301citations
- Q1SCImago
- 2018year
Short summary
The AASLD 2018 Hepatitis B Guidance updates recommendations for chronic hepatitis B (CHB), including new treatment options like tenofovir alafenamide, and guidance on screening, prevention, specialized testing, monitoring, and treatment in special populations.
AI-generated from the title and abstract; the full text is not read.
Key points
- Updated guidance on chronic hepatitis B (CHB) from AASLD 2018.
- Includes new treatment recommendations, notably tenofovir alafenamide.
- Provides guidance on screening, counseling, and prevention strategies.
- Covers specialized virological and serological testing.
- Addresses monitoring of untreated patients and treatment in special populations (coinfections, immunosuppression, transplant recipients).
AI-generated from the title and abstract; the full text is not read.
Abstract
This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients.
The authors' abstract, as published at the source. Hepatology, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Epidemiology
EpidemiologyMedicine